Compare ATEC & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATEC | HRMY |
|---|---|---|
| Founded | 1990 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.1B |
| IPO Year | 2006 | 2020 |
| Metric | ATEC | HRMY |
|---|---|---|
| Price | $13.90 | $37.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 8 |
| Target Price | $22.36 | ★ $49.75 |
| AVG Volume (30 Days) | ★ 4.2M | 616.4K |
| Earning Date | 02-24-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.44 |
| EPS | N/A | ★ 3.17 |
| Revenue | $728,020,000.00 | ★ $825,944,000.00 |
| Revenue This Year | $27.10 | $23.34 |
| Revenue Next Year | $16.77 | $16.28 |
| P/E Ratio | ★ N/A | $11.77 |
| Revenue Growth | ★ 27.11 | 21.13 |
| 52 Week Low | $8.81 | $25.52 |
| 52 Week High | $23.29 | $40.87 |
| Indicator | ATEC | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 26.75 | 48.18 |
| Support Level | $13.43 | $36.27 |
| Resistance Level | $15.55 | $38.04 |
| Average True Range (ATR) | 0.70 | 1.18 |
| MACD | -0.15 | -0.03 |
| Stochastic Oscillator | 6.91 | 50.14 |
Alphatec Holdings Inc is a medical technology company focused on the designing, development, and advancement of products for the surgical treatment of spinal disorders associated with disease and degeneration, congenital deformities, and trauma. The company's spine approach technologies include Posterior Cervical Fusion, Anterior Cervical Discectomy and Fusion, Lateral Interbody Fusion, and Posterior Lumbar Interbody Fusion among others.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.